SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer

BACKGROUND: Metastatic breast cancer exhibits diverse and rapidly evolving intra- and inter-tumor heterogeneity. Patients with similar clinical presentations often display distinct tumor responses to standard of care (SOC) therapies. Genome landscape studies indicate that EGFR/HER2/RAS “pathway” act...

Descripción completa

Detalles Bibliográficos
Autores principales: van Reesema, Lauren L. Siewertsz, Zheleva, Vasilena, Winston, Janet S., Jansen, Rick J., O’Connor, Carolyn F., Isbell, Andrew J., Bian, Minglei, Qin, Rui, Bassett, Patricia T., Hinson, Virginia J., Dorsch, Kimberly A., Kirby, Brad W., Van Sciver, Robert E., Tang-Tan, Angela M., Harden, Elizabeth A., Chang, David Z., Allen, Cynthia A., Perry, Roger R., Hoefer, Richard A., Tang, Amy H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049993/
https://www.ncbi.nlm.nih.gov/pubmed/27569656
http://dx.doi.org/10.1016/j.ebiom.2016.08.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049993/
https://www.ncbi.nlm.nih.gov/pubmed/27569656
http://dx.doi.org/10.1016/j.ebiom.2016.08.014

Ejemplares similares